Styliani S.
- Country
- Greece
- Department
- 1st Department of Internal Medicine
Research Overview
- Efficacy of Pancreatic Stone Protein-Guided Early Meropenem Administration to Mitigate Sepsis Risk in Patients Presenting to the Emergency Department: A Phase III RCT
- Adjunctive Clarithromycin to Prevent Secondary Infections in Patients with Community‑Acquired Pneumonia‑Related Sepsis and Sepsis‑Induced Immunoparalysis (CLASSIFY)
- Efficacy and Safety of Anakinra in Patients with Post-Acute COVID-19 Syndrome: A Double-Blind, Randomized, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 20 of 41 partner sites.
Specializations
Infectious Disease Management
This investigator specializes in the treatment of severe infections with particular emphasis on optimizing antibiotic therapy. Their research explores innovative approaches to reducing broad-spectrum antibiotic usage through procalcitonin-guided and molecular-guided diagnosis methods.
- Antimicrobial Stewardship
- Diagnostic Biomarkers
- Treatment Optimization
Sepsis Research
The investigator focuses on advanced therapeutic approaches for sepsis, particularly investigating the role of interferon-gamma endotypes. Their work includes evaluation of targeted immunotherapy interventions and biomarker-guided treatments for community-acquired pneumonia to prevent sepsis progression.
- Immunological Endotypes
- Targeted Antibody Therapy
- Sepsis Prevention Strategies
Post-COVID Conditions
This researcher investigates therapeutic solutions for Post-Acute COVID Syndrome (PACS), focusing on immune system modulation. Their work examines the efficacy of immunomodulatory treatments in addressing persistent respiratory symptoms and immune system activation in post-COVID patients.
- Long COVID Management
- Immune System Modulation
- Respiratory Symptom Treatment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.